Charming Medical Limited Class A Ordinary Shares(MCTA)Earnings, Financials & Key Ratios
MCTA•NASDAQ
$29.35
414.5× P/E·Price updated Jun 20, 2026
AboutCharming Medical Limited, through its subsidiaries, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. Its services includes womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, traditional Chinese medicine (TCM)-inspired prenatal massage, and Indonesian traditional abdominal binding. The company also provides TCM-inspired supplements products, which includes Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets; and beauty products, including ginseng soothing anti-allergy moisturizing wash for skin issues, and scalp health. In addition, it offers consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. Further, the company's products are used for the treatment of alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, uterine health, enhance physical weakness, balance endocrine functions, and other common women's health issues. it operates wellness centres. The company was founded in 2016 and is headquartered in Causeway Bay, Hong Kong.Show more
- Revenue$6M+3.4%
- EBITDA$2M+18.0%
- Net Income$1M+54.2%
- EPS (Diluted)0.07+54.2%
- Gross Margin67.19%+3.3%
- EBITDA Margin26.56%+14.1%
- Operating Margin22.32%+33.1%
- Net Margin19.27%+49.0%
- ROE2435.04%
MCTA Price & Volume
Charming Medical Limited Class A Ordinary Shares (MCTA) stock price & volume — 10-year historical chart
Loading chart...
Niche Wellness Margins Face Demographic Growth Constraints
Investment Thesis • Updated N/A
VerdictNeutral
Growth:Stable
Profitability:Moderate
Financial:Healthy
Cash Flow:Stable
Primary Risk:Demographic and geographic concentration
Key Thesis Takeaways
- Charming Medical Limited leverages proprietary TCM-integrated protocols to maintain a robust 67.19% gross margin, yet top-line expansion remains stagnant at 3.43% due to its hyper-localized focus in Causeway Bay.
- While the company maintains a conservative 23.57% debt-to-equity ratio, investors should monitor the long-term sustainability of its postpartum service model amidst Hong Kong's declining birth rates.
- The firm's reliance on deferred revenue for liquidity and its high fixed-cost real estate burden warrant caution regarding future scalability and earnings quality.
Verdict Logic
the current P/E ratio of 414.55 suggests that the market is pricing in significant future growth that is not currently supported by the stagnant 3.43% revenue expansion.
MCTA Growth Metrics
Charming Medical Limited Class A Ordinary Shares (MCTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years341.03%
5 Years341.03%
3 Years341.03%
Last Year341.03%
Peers Comparison
Key metrics vs top competitors for Charming Medical Limited Class A Ordinary Shares (MCTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.35 | $445.47M | 414.55 | 3.43% | 19.27% | 2435.04% | — | |
| $0.23 | $88.51M | -0.14 | 498.08% | -91.96% | -60.5% | — | |
| $5.00 | $2.59B | -29.41 | 40.34% | -2.58% | -17.08% | — | |
| $94.66 | $6.27B | 69.09 | 15.24% | 9.48% | 5.13% | — | |
| $1.65 | $537.3M | -5.32 | -30.65% | -146.01% | -0.11% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — |
Compare MCTA vs Peers
Charming Medical Limited Class A Ordinary Shares (MCTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MCTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MCTA Frequently Asked Questions
Charming Medical Limited Class A Ordinary Shares (MCTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Charming Medical Limited Class A Ordinary Shares's revenue?
Charming Medical Limited Class A Ordinary Shares (MCTA) reported $6.2M in revenue for fiscal year 2024. This represents a 76% increase from $3.5M in 2022.
How fast is Charming Medical Limited Class A Ordinary Shares growing?
Charming Medical Limited Class A Ordinary Shares (MCTA) grew revenue by 3.4% over the past year. Growth has been modest.
Is MCTA profitable?
Yes, Charming Medical Limited Class A Ordinary Shares (MCTA) is profitable, generating $1.2M in net income for fiscal year 2024 (19.3% net margin).
Dividend & Returns
What is MCTA's return on equity?
Charming Medical Limited Class A Ordinary Shares (MCTA) has a return on equity (ROE) of 2435.0%. This is excellent, indicating efficient use of shareholder capital.
What is Charming Medical Limited Class A Ordinary Shares's free cash flow?
Charming Medical Limited Class A Ordinary Shares (MCTA) generated $0.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.